TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has entered into an exclusive worldwide license agreement with Unleash Immuno Oncolytics, Inc., obtaining full development rights to three drug candidates: UIO-524, UIO-525, and UIO-526. This strategic acquisition includes all intellectual property rights previously held by Unleash, positioning TransCode to advance these next-generation therapies without future royalty obligations. In exchange, Unleash will receive 1,136,364 shares of a new series of non-voting convertible preferred stock, representing approximately 6.8% of TransCode's common stock on a fully diluted basis.
The lead candidate, UIO-524, represents a significant advancement in oncolytic virus technology. Engineered to selectively replicate within malignant cells and cancer-associated stroma, this therapy delivers a multi-cytokine immune-activating payload designed to stimulate the body's immune system against solid tumors. Initial clinical development will focus on muscle-invasive bladder cancer, a challenging malignancy with limited treatment options. This addition complements TransCode's existing oncology pipeline, which includes its lead asset TTX-MC138 currently advancing toward a Phase 2a clinical trial for metastatic cancers overexpressing microRNA-10b.
This licensing agreement carries substantial implications for cancer treatment development. Oncolytic viruses represent a promising frontier in immuno-oncology, offering the potential to selectively target cancer cells while activating systemic immune responses against tumors. The exclusive worldwide rights provide TransCode with complete control over development and commercialization strategies across all markets. For patients with solid tumors, particularly those resistant to conventional therapies, this expansion increases the likelihood of new treatment options reaching clinical testing and potentially approval.
The transaction structure, utilizing equity rather than cash payments, preserves TransCode's financial resources for research and development activities. This approach allows the company to advance multiple therapeutic candidates simultaneously while maintaining operational flexibility. The convertible preferred stock arrangement aligns the interests of both companies in the successful development of these drug candidates, as Unleash shareholders benefit directly from TransCode's progress.
For the broader oncology field, this agreement demonstrates continued investment in innovative treatment modalities beyond traditional chemotherapy and radiation. The combination of RNA therapeutics with oncolytic virus platforms represents a multi-pronged approach to cancer treatment that could address different aspects of tumor biology and resistance mechanisms. As TransCode integrates these new assets into its development pipeline, the company strengthens its position in the competitive immuno-oncology landscape while expanding its potential impact on cancer care worldwide. Additional information about TransCode Therapeutics is available at https://www.transcodetherapeutics.com, while updates relating to RNAZ can be found in the company's newsroom at https://ibn.fm/RNAZ.
